SinoFresh nasal spray looks promising in killing SuperBug
VENICE, Fla. Preliminary results indicate that SinoFresh HealthCare’s SinoFresh nasal spray is useful in controlling the virulent staphylococcus strain MRSA, SinoFresh announced Tuesday.
The company conducted a pilot animal study, which showed that the spray could kill MRSA bacteria living in the nasal passages when used three times daily. The study follows an in vitro study conducted at the Public Health Research Institute. SinoFresh’s nasal spray attacks the bacteria by physically destroying the bacteria’s cell walls and membranes.
MRSA, which stands for methicillin resistant staphylococcus aureas, is an antibiotic-resistant strain of staphylococcus that incubates in the nasal passages and can cause severe infections when it gets on the skin, leading to disfigurement and even death. As many as 3 million Americans are estimated to carry the bacteria.
Survivors from 1918 influenza may hold key to current vaccine
WASHINGTON Researchers have found that survivors of the 1918 influenza pandemic still have antibodies providing resistance to one of the deadliest viruses in modern history, according to the Associated Press.
The researchers did tests on 32 survivors—all aged 92 to 102—and found that the antibodies remained in their bloodstreams. They also manipulated the antibodies into a vaccine and injected it into mice, which became immune to the virus themselves.
This is the longest that cells targeting specific pathogens have lasted in people, the author of the study said.
FDA upholds decision not to approve PreMD’s skin cholesterol test
TORONTO A decision by the Food and Drug Administration to not approve an expanded use for a skin cholesterol test caused maker PreMD’s shares to fall by more than 50 percent Monday, according to Reuters.
The FDA’s decision affirmed a ruling it made in January, in which it cited defects in the design and data analysis of a study used to support the expansion.
The company had tried to overturn the FDA’s initial ruling, which concluded that its clinical trial data were not sufficient to show that the test was “substantially equivalent” to approved cardiovascular risk tests.
The company’s shares were worth 14 Canadian cents Monday. Earlier in the day, they had fallen below 10 Canadian cents.